low - Pre-revenue clinical-stage biotech with minimal direct GDP sensitivity. Cancer drug demand is non-discretionary and insulated from economic cycles. However, capital markets conditions affect ability to raise funding, and economic downturns can impact pharma partners' willingness to pursue licensing deals or acquisitions.

Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (zanidatamab revenue potentially 2027+). Clinical-stage biotechs trade at high P/S multiples (12.8x on minimal revenue) making them sensitive to risk-free rate changes. Higher rates also increase opportunity cost of capital for speculative growth investments. Minimal direct business impact as company has low debt (0.06 D/E) and holds cash in short-term instruments that benefit from higher yields.

growth - High-risk, high-reward clinical-stage biotech attracts speculative growth investors betting on binary clinical trial outcomes and potential acquisition by large pharma. 57% one-year return reflects momentum following positive clinical updates. Institutional biotech specialists and hedge funds with event-driven strategies dominate ownership. Not suitable for value or income investors given negative earnings, no dividends, and uncertain commercialization timeline.